Filing summary
Entity discrepancy: The request identifies TALPHERA, INC., but the supplied Form 10-Q is for AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX). This summary covers the filing provided, for the quarter ended September 30, 2022.
Business context and reporting period
AcelRx is a specialty pharmaceutical company focused on therapies for medically supervised settings. Its marketed products include DSUVIA in the United States and DZUVEO in Europe; its development portfolio includes ephedrine and phenylephrine pre-filled syringes and nafamostat candidates, including Niyad. The filing reports the three and nine months ended September 30, 2022, with comparisons to 2021.
Financial performance and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Total revenue | $0.5 million | $1.9 million | $1.5 million | $2.8 million |
| Product sales | $0.5 million | $0.2 million | $1.5 million | $1.0 million |
| Operating loss | $6.6 million | $8.6 million | $29.2 million | $27.8 million |
| Net income (loss) | $(6.8) million | $(8.4) million | $55.2 million | $(27.2) million |
| Operating cash used | Not provided for quarter | Not provided for quarter | $22.9 million | $22.0 million |
- Q3 product sales rose year over year; the filing attributes the increase partly to distributor purchases ahead of a price increase effective October 1, 2022. Management expects distributor inventory to decline over the following one or two quarters. The filing’s product-sales note allocates Q3 sales as $478,000 for DSUVIA and $29,000 for DZUVEO.
- Nine-month product sales increased 51%, but total revenue fell 46%, principally because the prior-year period included collaboration and license revenue not recorded in 2022. Cost of goods sold exceeded product sales by about $62,000 in Q3 and $710,000 for the nine-month period; gross margin was therefore negative.
- Nine-month net income was driven by an $84.1 million non-cash gain from terminating the royalty monetization liability, not by operating profitability. The company continued to report operating losses and negative operating cash flow.
- At September 30, cash and cash equivalents were $12.7 million, restricted cash was $5.0 million, and short-term investments were $3.2 million: $20.9 million combined, versus $51.6 million at December 31, 2021. Current assets were $24.5 million and current liabilities $15.7 million.
- Oxford debt had a reported balance of $7.4 million in the debt note; the balance sheet shows $7.9 million of current debt carrying value. The loan was scheduled to mature June 1, 2023. The loan also requires at least $5.0 million of unrestricted cash in controlled accounts.
Material changes and unusual items
- In May 2022, AcelRx terminated its royalty monetization arrangement with SWK for $0.1 million, extinguishing the related liability and recognizing the $84.1 million gain.
- The January 2022 Lowell acquisition added nafamostat assets, including Niyad. The company recorded an $8.8 million in-process research and development asset; up to $26.0 million of additional consideration is contingent on milestones.
- AcelRx recorded a $4.9 million non-cash impairment on Zalviso-related equipment and facility improvements. It does not expect to resubmit a U.S. Zalviso NDA in the foreseeable future and, following withdrawal of its European marketing authorization in July 2022, does not expect near-term European Zalviso revenue.
- The company reduced its workforce by approximately 40% in May, from 43 employees at the beginning of 2022 to 20 at September 30, primarily affecting the commercial organization. It reported approximately $0.5 million of related termination benefits, all paid.
- After quarter-end, the company completed a 1-for-20 reverse stock split on October 25, 2022, primarily to address Nasdaq’s minimum bid-price requirement. It also redeemed all 3,000 Series A preferred shares for approximately $0.3 million in October.
Outlook, risks, and contingencies
- Going concern: Management states that additional capital will be needed to fund planned operations before the 12-month anniversary of the filing. The filing says available capital would not fund operations for the next twelve months absent successful financing and identifies substantial doubt about the company’s ability to continue as a going concern. Financing plans—including equity, debt, asset monetization, refinancing, partnerships, or divestitures—are uncertain. Failure to raise funds could require further cuts or reductions in commercialization and development.
- Management is shifting resources toward the acquired development pipeline, including Niyad and the pre-filled syringes, while seeking a commercial partner to expand DSUVIA sales and reduce costs. No quantified revenue or earnings guidance is provided.
- COVID-19 restrictions on healthcare-facility access, delayed formulary decisions and elective procedures, and manufacturing/validation delays may continue to constrain DSUVIA sales and supply. Completion and regulatory acceptance of the automated packaging line remained pending.
- Key risks include dependence on DSUVIA commercialization and partner execution, regulatory and development uncertainty for pipeline candidates, opioid-related regulation and litigation, manufacturing and single-source supply risks, reimbursement and market acceptance, and the need for additional capital. Niyad’s EUA application is tied to the declared COVID-19 health emergency.
- A securities class action was dismissed by the court on September 28, 2022, with plaintiffs permitted to amend by November 28, 2022. Related consolidated derivative actions were stayed pending the class-action proceedings. The company says it cannot estimate a reasonably possible loss.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is AcelRx Pharmaceuticals, Inc., not TALPHERA, INC.
- Assess the company’s financing runway, restricted-cash requirement, debt maturity, and ability to secure capital on acceptable terms.
- Separate recurring operating performance and cash burn from the one-time $84.1 million accounting gain.
- Track DSUVIA sales after the October price increase, distributor inventory levels, and progress on a commercial partnership and automated packaging-line validation.
- Verify regulatory and development milestones for Niyad and the pre-filled syringe candidates, alongside contingent Lowell consideration and litigation developments.